Related Experiment Video
Updated: Nov 2, 2025
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy with Anti-VEGF Therapy
Aaron Lindeke-Myers1, Gregg T Kokame2,3,4,5,6, Steven Yeh1,7
1Emory University School of Medicine, Atlanta, GA.
Purpose:
To report a case of an 86-year-old man with a full thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab.
Methods:
A retrospective case report is presented.
Results:
An 86-year-old male presented with a five-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After four treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention.
Conclusions:
The patient's FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. MH formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment